LIXTE Biotechnology Reshapes Leadership, Appoints Peter Stazzone As CFO, Welcomes Lourdes Felix And Guy Primus To Board, Relocates HQ To Boca Raton

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company developing a new class of cancer therapies designed to enhance the effectiveness of chemotherapy and immunotherapy, has announced several important updates to its leadership team and operations. The company has welcomed Lourdes Felix and Guy Primus to its Board of Directors and appointed Peter Stazzone as its new Chief Financial Officer. Alongside these leadership changes, LIXTE has also relocated its corporate headquarters to Boca Raton, Florida.

The new appointments mark a transition in the company’s leadership structure. Felix takes on the role of Chair of LIXTE’s Audit Committee, succeeding Regina Brown, who has retired from the Board. She brings more than three decades of experience in management, corporate finance, and public accounting. Felix currently serves as Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx, Inc., a publicly traded company focused on developing programs for substance abuse and related disorders. She has been with BioCorRx since 2012 and also serves as a director on three additional Nasdaq-listed companies.

Primus joins the Board with a strong background in business leadership and innovation, having spent over 30 years in technology-driven organizations. He co-founded and served as Chief Executive Officer of The Virtual Reality Company and has held senior roles at Starbucks and Microsoft. In addition to his corporate leadership, Primus has contributed to advancing technology in healthcare systems and previously chaired Georgia Tech’s School of Industrial and Systems Engineering Advisory Board, a program recognized worldwide for its leadership in health systems.

Geordan Pursglove, who became LIXTE’s Chairman and Chief Executive Officer in June 2025, stated, “We are thrilled to welcome Peter, Lourdes and Guy to the LIXTE family. They each bring exceptional expertise, fresh perspective, and a deep commitment that will strengthen the Company as it evaluates new business opportunities. We are fortunate that Bas and René will continue to be part of our team, focusing their attention on further development of the Company’s proprietary compound, LB-100, and LIXTE’s mission of developing and delivering effective solutions to patients battling cancer. The move of our corporate offices to Florida enhances our ability to operate efficiently in a business-friendly environment that reduces costs and is in keeping with our commitment to creating long-term value for shareholders.”

Stazzone assumes the role of Chief Financial Officer, succeeding Robert Weingarten, who has stepped down to pursue other opportunities. With more than 20 years of financial management experience in both public and private companies, Stazzone has played a pivotal role in guiding corporate transformations through mergers and acquisitions, capital raising, financial controls, and public company reporting. His previous CFO roles include Beyond Commerce, Inc., Strainz, Inc., and Voice Telecom.

The company also announced changes in its scientific leadership. Bas van der Baan will continue in his role as Chief Scientific Officer, while René Bernards, PhD, has been appointed Chairman of LIXTE’s Scientific Advisory Board, strengthening the company’s focus on advancing its pipeline of innovative cancer therapies.